Journal
NEUROLOGICAL SCIENCES
Volume 39, Issue 8, Pages 1423-1430Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-018-3442-y
Keywords
Relapsing-remitting multiple sclerosis; Beta interferon; Glatiramer acetate; Oligoclonal M bands
Categories
Ask authors/readers for more resources
To study the efficacy of interferon beta (IFN beta) and glatiramer acetate (GA) related to the presence of oligoclonal M bands (OCMB) in the cerebrospinal fluid in relapsing-remitting multiple sclerosis (RRMS). This is an observational, multicenter and retrospective study with prospectively collected data of patients that started treatment with IFN beta or GA. Treatment decision was made blinded to the OCMB status. Time to first attack after starting therapy was compared by using Kaplan-Meier curves, and adjustment by Cox regression analysis was performed. Two hundred and fifty-six patients entered in the study (141-55% received IFN beta; 115-45% received GA). After a mean follow-up of 41 and 65 months, 54.7% of patients remained free from further attacks (RF). The proportion of RF patients was higher in the GA group than in the IFN beta group (72.2 vs. 40.4%, p < 0.001). The IFN beta patients with OCMB+ presented the poorest response, 31.3% RF vs. 48.1% in IFN beta without OCMB, p = 0.03. OCMB in CSF could be a biomarker of treatment response in multiple sclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available